DRUG

Bright Minds Biosciences Inc

Healthcare · Biotechnology

53.50$ -7.6% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Cash Flow

Bright Minds Biosciences Inc (DRUG) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -8.4 million CAD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of CAD.

Tick rows to compare them in a chart (up to 4)

Cash Flow DRUG
Line item	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Operating Cash Flow	-1.2	-0.8	-0.8	0.2	-0.5	-1.5	-2.4	-3.5	-1.3	-5.8	-9.5	-8.4	-25
Depreciation & Amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Stock-Based Compensation	0.4	0.2	0.2	0.2	0.2	0.2	0.6	1.3	1.1	1.3	1.2	1.5	5.1
Change in Working Capital	-0.3	0.6	-0.5	-0.2	0.1	-0.1	-0.1	-0.4	1.2	-1.0	1.4	-1.2	0.4
Capital Expenditures	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Borrowings	–	–	–	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1
Financing Cash Flow	0.0	0.9	0.0	0.0	0.0	52	0.2	0.0	33	13	232	-2.2	277
Change in Cash	-1.4	0.0	-0.8	0.3	-0.5	52	-2.2	-4.3	32	6.1	219	-7.0	250
Free Cash Flow	-1.2	-0.8	-0.8	0.2	-0.5	-1.5	-2.4	-3.5	-1.3	-5.8	-9.5	-8.4	-25

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Cash Flow

Cookie settings